Gardiner BJ, et al. – This study sought to assess the effect of secondary prophylaxis (SP) with valganciclovir on the risk of relapse in solid organ transplant recipients (SOTR) following an episode of Cytomegalovirus (CMV) disease. Findings suggested no long–term protection against relapse with the use of SP following treatment of CMV disease, although it did delay relapse while patients were receiving antivirals. Thereby indicating limited clinical utility of SP in the overall prevention of recurrent CMV disease.